XML 30 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Note 4 - Acquisitions and Divestitures (Details Textual)
€ in Millions, $ in Millions
3 Months Ended
Oct. 11, 2019
USD ($)
Jul. 12, 2019
USD ($)
Oct. 22, 2018
USD ($)
Oct. 22, 2018
EUR (€)
Sep. 20, 2018
USD ($)
Apr. 05, 2018
USD ($)
Mar. 31, 2020
Jun. 30, 2018
USD ($)
Oct. 22, 2018
EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)             10 years 73 days    
Reddick Divestiture [Member]                  
Proceeds from Sale of Productive Assets, Total           $ 7.4      
Long-term Purchase Commitment, Period (Year)           2 years      
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total               $ 5.9  
CardioCel and VascuCel Biologic Patches [Member]                  
Payments to Acquire Businesses, Gross $ 14.2                
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year) 10 years 146 days                
CardioCel and VascuCel Biologic Patches [Member] | Achieving Audited Financial Statements of Acquired Business [Member]                  
Payments to Acquire Businesses, Gross $ 0.3                
CardioCel and VascuCel Biologic Patches [Member] | First Holdback [Member]                  
Business Combination, Contingent Consideration, Liability, Total 0.7                
CardioCel and VascuCel Biologic Patches [Member] | Second Holdback [Member]                  
Business Combination, Contingent Consideration, Liability, Total 0.7                
CardioCel and VascuCel Biologic Patches [Member] | Third Holdback [Member]                  
Business Combination, Contingent Consideration, Liability, Total 2.0                
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty Million in the First Twelve Month Period After Closing Date [Member]                  
Business Combination, Contingent Consideration, Liability, Total 2.5                
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Fifteen Million in the First Twelve Month Period After Closing Date [Member]                  
Business Combination, Contingent Consideration, Liability, Total 1.2                
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Thirty Million in the Second Twelve Month Period After Closing Date [Member]                  
Business Combination, Contingent Consideration, Liability, Total 2.5                
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty-Two and a Half Million in the First Twelve Month Period After Closing Date [Member]                  
Business Combination, Contingent Consideration, Liability, Total 1.2                
CardioCel and VascuCel Biologic Patches [Member] | Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]                  
Business Combination, Contingent Consideration, Liability, Total 0.5                
CardioCel and VascuCel Biologic Patches [Member] | Technology Licenses [Member]                  
Business Combination, Consideration Transferred, Total 8.0                
CardioCel and VascuCel Biologic Patches [Member] | Maximum [Member] | Biological Patch Business Assets [Member]                  
Business Combination, Consideration Transferred, Total $ 15.3                
Tru-Incise Valve Cutter [Member]                  
Business Combination, Consideration Transferred, Total   $ 8.0              
Payments to Acquire Businesses, Gross   $ 6.8              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)   11 years 292 days              
Business Combination, Deferred Purchase Consideration, Installment Payment   $ 0.4              
Business Combination, Deferred Purchase Consideration   1.2              
Acquisition Date Fair Value   $ 1.1              
Business Combination ,Fair Value Inputs, Discount Rate   4.19%              
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period (Year)   15 years              
Cardial [Member]                  
Business Combination, Consideration Transferred, Total     $ 2.3 € 2.0          
Payments to Acquire Businesses, Gross     $ 1.3 € 1.1          
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)     9 years 146 days 9 years 146 days          
Business Combination, Deferred Purchase Consideration     $ 0.4           € 0.4
Business Combination, Consideration Transferred, Liabilities Incurred     0.5 € 0.5          
Deferred Tax Assets, Business Combinations     0.6           € 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount     $ 1.6 € 1.4          
Applied Medical [Member]                  
Business Combination, Consideration Transferred, Total         $ 14.2        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)         13 years        
Acquisition Date Fair Value         $ 3.0        
Business Combination ,Fair Value Inputs, Discount Rate         3.75%        
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period (Year)         15 years        
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs         $ 3.2        
Applied Medical [Member] | Closing Date [Member]                  
Business Combination, Consideration Transferred, Total         11.0        
Applied Medical [Member] | 12 Months Following the Closing Date [Member]                  
Business Combination, Consideration Transferred, Total         2.0        
Applied Medical [Member] | 24 Months Following the Closing Date [Member]                  
Business Combination, Consideration Transferred, Total         $ 1.2        
Balloon Supply Agreement [Member] | Reddick Divestiture [Member]                  
Long-term Purchase Commitment, Period (Year)           6 years